Classification of JAK1 Inhibitors and SAR Research by Machine Learning Methods

被引:5
作者
Yang, Zhenwu [1 ]
Tian, Yujia [1 ]
Kong, Yue [3 ]
Zhu, Yushan [2 ]
Yan, Aixia [1 ]
机构
[1] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53,15 BeiSanHuan East Rd, Beijing 100029, Peoples R China
[2] Beijing Univ Chem Technol, Coll Life Sci & Technol, Natl Energy R&D Ctr Biorefinery, Beijing 100029, Peoples R China
[3] Hyperdimens Insight Pharmaceut Ltd, Room 511,Block A,2 C,DongSanHuan North Rd, Beijing, Peoples R China
来源
ARTIFICIAL INTELLIGENCE IN THE LIFE SCIENCES | 2022年 / 2卷
关键词
Deep neural networks (DNN); Janus kinase 1 (JAK1) inhibitor; Molecular modeling; Structure-activity relationship; Substructure analysis; JANUS KINASE 1; RHEUMATOID-ARTHRITIS; DUAL INHIBITORS; DISCOVERY; DERIVATIVES; POTENT; DOCKING; DESIGN; IDENTIFICATION; PHARMACOPHORE;
D O I
10.1016/j.ailsci.2022.100039
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Janus kinase 1 (JAK1) is a key regulator of gene transcription, inhibition of JAK1 is an intervention for many diseases including rheumatoid arthritis and Crohn's disease. In this study, we collected a dataset containing 2982 JAK1 inhibitors, characterized molecules by MACCS fingerprints and Morgan fingerprints. We used support vector machine (SVM), decision tree (DT), random forest (RF) and extreme gradient boosting tree (XGBoost) algorithms to build 16 traditional machine learning classification models. Additionally, we utilized deep neural networks (DNN) to develop four deep learning models. The best model (Model 3B) built by RF and Morgan fingerprints achieved the accuracy (ACC) of 93.6% and Mathews correlation coefficient (MCC) of 0.87 on the test set. Furthermore, we made structure-activity relationship (SAR) analyses for JAK1 inhibitors, based on the output from the random forest models. After analyzing the important keys of two types of fingerprints, it was observed that some substructures such as pyrazole, pyrrolotriazolopyrimidine and pyrazolopyrimidine appeared frequently in highly active JAK1 inhibitors.
引用
收藏
页数:14
相关论文
共 140 条
[31]   A Selective, Orally Bioavailable 1,2,4-Triazolo[1;5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 [J].
Dugan, Benjamin J. ;
Gingrich, Diane E. ;
Mesaros, Eugen F. ;
Milkiewicz, Karen L. ;
Curry, Matthew A. ;
Zulli, Allison L. ;
Dobrzanski, Pawel ;
Serdikoff, Cynthia ;
Jan, Mahfuza ;
Angeles, Thelma S. ;
Albom, Mark S. ;
Mason, Jennifer L. ;
Aimone, Lisa D. ;
Meyer, Sheryl L. ;
Huang, Zeqi ;
Wells-Knecht, Kevin J. ;
Ator, Mark A. ;
Ruggeri, Bruce A. ;
Dorsey, Bruce D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (11) :5243-5254
[32]   Upadacitinib: First Approval [J].
Duggan, Sean ;
Keam, Susan J. .
DRUGS, 2019, 79 (16) :1819-1828
[33]  
Fensome A, 2015, US Pat, Patent No. US9663526US2016052930(A1)
[34]  
Fensome A, 2015, US Pat, Patent No. US9663526US2016052930(A1)
[35]   Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-(1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) [J].
Fensome, Andrew ;
Ambler, Catherine M. ;
Arnold, Eric ;
Banker, Mary Ellen ;
Brown, Matthew F. ;
Chrencik, Jill ;
Clark, James D. ;
Dowty, Martin E. ;
Efremov, Ivan V. ;
Flick, Andrew ;
Gerstenberger, Brian S. ;
Gopalsamy, Ariamala ;
Hayward, Matthew M. ;
Hegen, Martin ;
Hollingshead, Brett D. ;
Jussif, Jason ;
Knafels, John D. ;
Limburg, David C. ;
Lin, David ;
Lin, Tsung H. ;
Pierce, Betsy S. ;
Saiah, Eddine ;
Sharma, Raman ;
Symanowicz, Peter T. ;
Telliez, Jean-Baptiste ;
Trujillo, John I. ;
Vajdos, Felix F. ;
Vincent, Fabien ;
Wan, Zhao-Kui ;
Xing, Li ;
Yang, Xiaojing ;
Yang, Xin ;
Zhang, Liying .
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (19) :8597-8612
[36]   Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection [J].
Flanagan, Mark E. ;
Blumenkopf, Todd A. ;
Brissette, William H. ;
Brown, Matthew F. ;
Casavant, Jeffrey M. ;
Shang-Poa, Chang ;
Doty, Jonathan L. ;
Elliott, Eileen A. ;
Fisher, Michael B. ;
Hines, Michael ;
Kent, Craig ;
Kudlacz, Elizabeth M. ;
Lillie, Brett M. ;
Magnuson, Kelly S. ;
McCurdy, Sandra P. ;
Munchhof, Michael J. ;
Perry, Bret D. ;
Sawyer, Perry S. ;
Strelevitz, Timothy J. ;
Subramanyam, Chakrapani ;
Sun, Jianmin ;
Whipple, David A. ;
Changelian, Paul S. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) :8468-8484
[37]   TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial [J].
Forman, Seth B. ;
Pariser, David M. ;
Poulin, Yves ;
Vincent, Michael S. ;
Gilbert, Steven A. ;
Kieras, Elizabeth M. ;
Qiu, Ruolun ;
Yu, Dahong ;
Papacharalambous, Jocelyne ;
Tehlirian, Christopher ;
Peeva, Elena .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (12) :2359-+
[38]  
Fratello M, 2019, Decision Trees and Random Forests
[39]  
Gabrielson SW, 2018, Journal of the Medical Library Association, P106
[40]   Structural insights of JAK2 inhibitors: pharmacophore modeling and ligand-based 3D-QSAR studies of pyrido-indole derivatives [J].
Gade, Deepak Reddy ;
Kunala, Pavan ;
Raavi, Divya ;
Reddy, Pavan Kumar K. ;
Prasad, Rajendra V. V. S. .
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2015, 35 (02) :189-201